Merck (MRK) Shares Outstanding (2009 - 2026)
Merck (MRK) posted quarterly Shares Outstanding (Entity) of $2.5 billion for Q1 2026, down 2.02% year-over-year from $2.5 billion in Q1 2025, and down 1.2% quarter-over-quarter from $2.5 billion in Q4 2025.
Merck (MRK) Shares Outstanding (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Shares Outstanding (Entity) for 18 consecutive years, with $2.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) fell 2.02% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (down 2.02% YoY), while the FY2025 annual figure was $2.5 billion, down 1.18% from the prior year.
- Shares Outstanding (Entity) fell to $2.5 billion in Q1 2026 per MRK's latest filing, from $2.5 billion in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $2.5 billion in Q2 2023 and bottomed at $2.5 billion in Q1 2026.
- Historically, Shares Outstanding (Entity) has averaged $2.5 billion across 5 years, with a median of $2.5 billion in 2022.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) grew 0.4% — and 2026, when it slipped 2.02%.
- Merck's Shares Outstanding (Entity) stood at $2.5 billion in 2022, then gained by 0.2% to $2.5 billion in 2023, then decreased by 0.2% to $2.5 billion in 2024, then decreased by 1.18% to $2.5 billion in 2025, then dropped by 1.2% to $2.5 billion in 2026.
- Business Quant data shows MRK's Shares Outstanding (Entity) at $2.5 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.47 Bn |
| Mar 31, 2026 | 2.47 Bn |
| Dec 31, 2025 | 2.50 Bn |
| Sep 30, 2025 | 2.50 Bn |
| Jun 30, 2025 | 2.51 Bn |
| Mar 31, 2025 | 2.52 Bn |
| Dec 31, 2024 | 2.53 Bn |
| Sep 30, 2024 | 2.53 Bn |
| Jun 30, 2024 | 2.53 Bn |
| Mar 31, 2024 | 2.53 Bn |
| Dec 31, 2023 | 2.54 Bn |
| Sep 30, 2023 | 2.54 Bn |
| Jun 30, 2023 | 2.54 Bn |
| Mar 31, 2023 | 2.54 Bn |
| Dec 31, 2022 | 2.53 Bn |
| Sep 30, 2022 | 2.53 Bn |
| Jun 30, 2022 | 2.53 Bn |
| Mar 31, 2022 | 2.53 Bn |
| Dec 31, 2021 | 2.53 Bn |
| Sep 30, 2021 | 2.53 Bn |